Objective:
To discuss the resurgence of neuroprotection in glaucoma treatment and future strategies.
Key Findings:
- Current glaucoma treatments are inadequate for many patients.
- The DLK/LZK pathway is a significant target for neuroprotective strategies.
- AI can enhance trial designs by predicting patient progression.
- Topical insulin and neurotrophins show promise as neuroprotective agents.
- Patient compliance remains a critical challenge in glaucoma treatment.
Interpretation:
Neuroprotection represents a promising shift in glaucoma management, addressing limitations of current therapies focused on intraocular pressure.
Limitations:
- Regulatory agencies currently require visual benefits for drug approval.
- Changing established treatment practices among ophthalmologists may take time.
Conclusion:
The future of glaucoma treatment may increasingly incorporate neuroprotective strategies, especially for patients who do not respond to traditional therapies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
